Literature DB >> 8353289

Junctions of the AML1/MTG8(ETO) fusion are constant in t(8;21) acute myeloid leukemia detected by reverse transcription polymerase chain reaction.

T Kozu1, H Miyoshi, K Shimizu, N Maseki, Y Kaneko, H Asou, N Kamada, M Ohki.   

Abstract

The chromosomal translocation, t(8;21), is found frequently in acute myeloid leukemia (AML) with maturation (FAB-M2). We have previously mapped the translocation breakpoints of t(8;21) in a specific intron of the AML1 gene on chromosome 21. In this study, we cloned cDNAs synthesized from a cell line carrying t(8;21) by reverse transcription polymerase chain reaction (RT-PCR) using an AML1-specific primer. The analysis of the cDNAs structure has led to the identification of the fusion of AML1 with a gene named MTG8 on chromosome 8, which seems to be identical to ETO. Northern analysis using MTG8 (ETO) probes detected 7.8-kb and 6.2-kb RNAs and several minor RNAs in the cell line with t(8;21), but failed to detect any transcripts in a cell line without t(8;21). A set of primers were designed to detect the AML1/MTG8(ETO) fusion by PCR. The PCR amplified identical products in all 6 patients and one cell line with t(8;21), suggesting that the AML1/MTG8(ETO) fusion is a constant feature associated with t(8;21) and the junctions of the AML1/MTG8(ETO) fusion are restricted in a unique site. Because the PCR detection of the AML1/MTG8(ETO) fusion at the RNA level is highly sensitive, it can be used as a sensitive method for diagnosis and detection of minimal residual disease in t(8;21) leukemia.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8353289

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  27 in total

1.  Deletion of an AML1-ETO C-terminal NcoR/SMRT-interacting region strongly induces leukemia development.

Authors:  Ming Yan; Sebastien A Burel; Luke F Peterson; Eiki Kanbe; Hiromi Iwasaki; Anita Boyapati; Robert Hines; Koichi Akashi; Dong-Er Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-29       Impact factor: 11.205

2.  Interaction and functional cooperation of the leukemia-associated factors AML1 and p300 in myeloid cell differentiation.

Authors:  I Kitabayashi; A Yokoyama; K Shimizu; M Ohki
Journal:  EMBO J       Date:  1998-06-01       Impact factor: 11.598

3.  The t(8;21) chromosomal translocation in acute myelogenous leukemia modifies intranuclear targeting of the AML1/CBFalpha2 transcription factor.

Authors:  S McNeil; C Zeng; K S Harrington; S Hiebert; J B Lian; J L Stein; A J van Wijnen; G S Stein
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

4.  Designing of chimeric DNA/RNA hammerhead ribozymes to be targeted against AML1/MTG8 mRNA.

Authors:  T Kozu; E Sueoka; S Okabe; N Sueoka; A Komori; H Fujiki
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

5.  Subcellular localization of the alpha and beta subunits of the acute myeloid leukemia-linked transcription factor PEBP2/CBF.

Authors:  J Lu; M Maruyama; M Satake; S C Bae; E Ogawa; H Kagoshima; K Shigesada; Y Ito
Journal:  Mol Cell Biol       Date:  1995-03       Impact factor: 4.272

6.  Alternative splicing and genomic structure of the AML1 gene involved in acute myeloid leukemia.

Authors:  H Miyoshi; M Ohira; K Shimizu; K Mitani; H Hirai; T Imai; K Yokoyama; E Soeda; M Ohki
Journal:  Nucleic Acids Res       Date:  1995-07-25       Impact factor: 16.971

7.  Oligomerization of ETO is obligatory for corepressor interaction.

Authors:  J Zhang; B A Hug; E Y Huang; C W Chen; V Gelmetti; M Maccarana; S Minucci; P G Pelicci; M A Lazar
Journal:  Mol Cell Biol       Date:  2001-01       Impact factor: 4.272

8.  Recurrence of acute myelogenous leukemia with the same AML1/ETO breakpoint as at diagnosis after complete remission lasting 15 years: analysis of stored bone marrow smears.

Authors:  Norifumi Tsukamoto; Masamitsu Karasawa; Yoko Tanaka; Akihiko Yokohama; Hideki Uchiumi; Takafumi Matsushima; Hirokazu Murakami; Yoshihisa Nojima
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.490

9.  Supraphysiologic levels of the AML1-ETO isoform AE9a are essential for transformation.

Authors:  Kevin A Link; Shan Lin; Mahesh Shrestha; Melissa Bowman; Mark Wunderlich; Clara D Bloomfield; Gang Huang; James C Mulloy
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-25       Impact factor: 11.205

10.  PEBP2 alpha B/mouse AML1 consists of multiple isoforms that possess differential transactivation potentials.

Authors:  S C Bae; E Ogawa; M Maruyama; H Oka; M Satake; K Shigesada; N A Jenkins; D J Gilbert; N G Copeland; Y Ito
Journal:  Mol Cell Biol       Date:  1994-05       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.